

February 10, 2017

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Sub: Errata in press release

We refer to the press release submitted by the Company on February 10, 2017 on the quarterly results for the quarter ended December 31, 2016.


There was an inadvertent error, i.e., under Consolidated Financial Performance (Q3FY17 vs Q3FY16), we have mentioned that "Net Loss at Rs. 82 mn as against a loss of Rs. 84 mn in Q3FY16" whereas it should read as "Net Loss at Rs. 29 mn as against a loss of Rs. 109 mn in Q3FY16".


We attach herewith a corrected press release which we request you to upload in place of the press release sent on February 10, 2017.

We deeply regret the error.

Thanking you,

Yours faithfully,
For Sequent Scientific Limited


Preetham Hebbar
Company Secretary



SeQuent Scientific Limited

Corporate Office : 2nd Floor, "GALAXY" Plot No. 30, 1st Main Road, 3rd Phase, J. P. Nagar, (Behind Gopalan Mall), Bangalore - 560078 Tel.: 080 46570300
e-mail: infor@sequent.in www.sequent.in L99999MH1985PLC036685

Regd. Office : 301, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagale Estate Indl. Area, Thane (W) - 400 604, India. Tel.: +91-22-41114777 Fax: +91-22-41114754

Tarapur Plant : W-150, W-151, W-152, W-136, W-137, W-138, W-139, MIDC Ind. Area, Tarapur, Boisar, Dist. Thane - 401 504. Tel. : 02525-276111 Telefax : 02525-276112

Managlore Plant : 120 A & B Industrial Area, Baikemba, New Managlore - 575011, Karnataka. Tel -0824-2402100

SeQuent Scientific Announces Q3FY17 Financial Results

Consolidated Sales at Rs. 2,770 mn, up by 78%

Animal Health biz drives growth, run-rate revenues of Rs. 8,000 mn+

EBITDA from Continuing Operations at Rs. 333 mn, up by 274%

Mumbai, February 10, 2017: SeQuent Scientific Limited, a leading Integrated Pharmaceutical Company with business across Animal Health, Niche Human Health & Women Healthcare today announced its financial results for the third quarter (Q3FY17) and nine months (9MFY17) ended December 31, 2016.

Financial Highlights

Continuing business(Q3FY17 vs Q3FY16)*

- Revenue at Rs. 2,625 mn as against Rs. 1552 mn in Q3FY16, up by 69%
- Operating EBITDA at Rs. 333 mn, as against Rs. 89 mn, up by 274%
- Operating EBITDA margins at 12.7% in Q3FY17, an increase of 700 bps

**excluding Women Health (NAARI)*

Consolidated Financial Performance (Q3FY17 vs Q3FY16)

- Revenue at Rs. 2,770 mn as against Rs. 1,552 mn in Q3FY16, up by 78%.
- Operating EBITDA at Rs. 290 mn as against Rs. 89 mn in Q3FY16, up by 225%
- EBITDA Margin at 10.5% as against 5.7% in Q3FY16, improvement of 480bps
- Translation impact of Rs. 106 mn due to depreciation of Turkish Lira
- Net Loss at Rs. 29 mn as against a loss of Rs. 109 mn in Q3FY16

Commenting on the Company's performance for Q3FY17, **Manish Gupta, Managing Director** said *"We are pleased with the way our Animal Health Business is shaping up which is also reflected in the performance of the reported quarter. As our execution focus continues to play its part, this business has now achieved both scale and capabilities to drive margins and sustainable growth. With Alivira emerging as India's largest integrated veterinary company with run-rate revenues in excess of \$ 120 mn(Rs. 8,000 mn) per annum, SeQuent has drawn up a road map to becoming a pure-play Animal Health Company and create disruptive value for the stakeholders by announcing its intent to divest Human API business and Women Healthcare business"*

Operational update in Q3FY17

- Launched 4 new formulations in Europe in Alivira
- 7 product filings, 12 product approvals and 1 new launch in emerging markets for Alivira
- Global R&D Product development initiated for 5 products in Spain and India
- Turkey operations back on track in compliance with new GMP regime

For Sequent Scientific Limited


Prashant Hebbar
Company Secretary

- APIs - 8 new filings in Alivira, 1 in human API

Corporate Actions

The Board of Directors at their meeting held on February 3, 2017 approved in principle demerger of Human API Business to a separate entity to be listed in BSE / NSE and divesting Women Healthcare business to focus on Alivira (Integrated Animal Healthcare business) for disproportionate value creation. [Please click here for detailed press note issued on February 3, 2017](#)

Changes in Key Management Personnel

- The Company has relocated its Corporate Office from Bengaluru to Thane and on account of this Mr. Kannan.PR, who is the Chief Financial Officer and Mr. Preetham Hebbar, Company Secretary has expressed their desire to pursue other opportunities.
- The Board has appointed Mr. Tushar Mistry, who is with the Company for over 2 years as Vice President – Finance as the Chief Financial Officer. Mr. Krupesh Mehta has been appointed as the Company Secretary and Compliance Officer.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health APIs and formulations (Alivira), Human APIs, Women Healthcare (Naari) and Analytical Services. Headquartered in Mumbai, India, SeQuent has 11 manufacturing facilities based in India, Turkey, Spain and Brazil with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. For details, please contact

Tushar Mistry

Chief Financial Officer

Tel: +91 80 4657 0306

tushar.m@sequent.in

Ankit Gupta

Christensen Investor Relations

Tel : +91 22 4215 0210

ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685


BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Sequent Scientific Limited


Preetham Hebbar
Company Secretary